Celldex Therapeutics, Inc.
CLDX
$18.30
$0.502.81%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.99% | 128.55% | 155.05% | 92.76% | 192.02% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.99% | 128.55% | 155.05% | 92.76% | 192.02% |
| Cost of Revenue | 35.54% | 28.27% | 36.26% | 7.73% | 14.58% |
| Gross Profit | -38.19% | -22.95% | -30.78% | -4.71% | -9.34% |
| SG&A Expenses | 24.69% | 29.41% | 30.73% | 23.97% | 13.68% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 35.70% | 32.33% | 37.81% | 31.39% | 36.06% |
| Operating Income | -37.34% | -29.21% | -34.67% | -29.72% | -32.63% |
| Income Before Tax | -11.62% | -23.65% | -32.78% | -22.12% | -25.91% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.62% | -23.65% | -32.78% | -22.12% | -25.91% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.62% | -23.65% | -32.78% | -22.12% | -25.91% |
| EBIT | -37.34% | -29.21% | -34.67% | -29.72% | -32.63% |
| EBITDA | -38.02% | -29.71% | -35.26% | -30.24% | -33.43% |
| EPS Basic | 15.95% | 2.69% | -14.24% | -12.67% | -21.42% |
| Normalized Basic EPS | 8.39% | 11.79% | -4.24% | -11.34% | -20.13% |
| EPS Diluted | 16.08% | 3.00% | -13.84% | -12.67% | -21.41% |
| Normalized Diluted EPS | 8.39% | 11.79% | -4.24% | -11.34% | -20.13% |
| Average Basic Shares Outstanding | 32.92% | 28.78% | 18.92% | 9.25% | 3.31% |
| Average Diluted Shares Outstanding | 32.92% | 28.78% | 18.92% | 9.25% | 3.31% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |